Key Highlights

  • Ping An Biomedical Co., Ltd. (NASDAQ:PASW) changed hands at USD 1.70, a fall of 41.98% during trading on November 5, 2026, according to published market data, with about 67,000 shares traded.
  • On November 4, 2026 the firm disclosed a final agreement to acquire three tumor cell patents from Future Biotechnology Group Co., Limited, priced at USD 2.3 million.
  • The transaction builds on a non-binding letter of intent dated October 22, 2026, and closing plus registration steps remain open.
  • Published coverage says a 1-for-40 reverse split was announced on October 21, 2026, and one Shareholder controls roughly 91.56% of voting power.

A Patent Deal Signals a Shift Into Biomedicine

The company, Ping An Biomedical Co., Ltd. (NASDAQ:PASW), said on November 4, 2026 that it entered a final agreement to take over three tumor cell related medical technology patents from Future Biotechnology Group Co., Limited for USD 2.3 million. Those patents span oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe work. A non-binding letter of intent dated October 22, 2026 came first. The release did not specify how payment would be made, and closing and registration are still outstanding. A distinct strategic Investment proposal aimed at the seller is still being negotiated.

A Legacy Apparel Supply Chain Business Turning Course

The Cayman Islands Holding Company operates through a Chinese Subsidiary that manages supply chains for apparel makers, handling yarn, textiles and finished garments. Acquiring cancer-related patents therefore marks a sharp turn, and patents generate no Revenue until they are developed, licensed or commercialized. A shelf registration sets out plans to offer up to USD 300 million in securities, and in February 2026 the company agreed to sell 100 million ordinary shares at USD 0.04 each, raising USD 4 million. The 1-for-40 reverse split announced October 21, 2026 combines every 40 shares into one, lifting the quoted price while leaving company value unchanged.

Risks Tied to Thin Trading, Control and Dilution

With a Market Value of about USD 5 million per published market data, a few trades can move the price, spreads can be wide and quoted moves can reverse, so the drop should not be taken as a trend. Roughly 91.56% of voting power rests with a single shareholder, which limits the influence of outside holders. A shelf of that size relative to the company raises dilution risk, and reverse splits often come before more share issuance. The price also depends on meeting the Nasdaq minimum bid price requirement. Track the patent deal closing, payment terms and the result of the Future Biotechnology Group investment talks.

Where Things Stand

Ping An Biomedical Co., Ltd. (NASDAQ:PASW) declined because a very thinly traded stock is repricing a strategic pivot whose Economics remain unclear. The USD 2.3 million patent purchase has no disclosed payment method, closing is pending, and the legacy apparel operation offers little clue how the patents will produce revenue. Heavy voting control and a large shelf add dilution risk, and the quoted move is intraday and may reverse. The next signposts are the patent deal closing and any decision on the strategic investment.